Clover’s COVID-19 Vaccine Efficacy Data Published in The Lancet
China-based Clover Biopharmaceuticals, Ltd. announced on January 20, 2022, that final efficacy data from SPECTRA, a global clinical trial evaluating its protein-based COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), has been published in the peer-reviewed journal, The Lancet.
This data indicates that SCB-2019 (CpG 1018/Alum) achieved primary and secondary efficacy endpoints.
The COVID-19 vaccine candidate also demonstrated 100% efficacy against severe COVID-19 and hospitalization caused by any strain of SARS-CoV-2 in SPECTRA.
And SCB-2019 (CpG 1018/Alum) showed a favorable safety profile with no significant differences observed in systemic adverse events or severe adverse events when compared to placebo.
"We are pleased to have the SPECTRA pivotal Phase 2/3 trial results for Clover's COVID-19 vaccine candidate peer-reviewed and selected for publication in The Lancet," stated Dr. Ralf Clemens, Chairman of the Vaccine Scientific Advisory Board of Clover Biopharmaceuticals, in a press statement issued on January 20, 2022.
"SCB-2019 (CpG 1018/Alum) demonstrated high efficacy in an environment where all of the sequenced strains were variants, and no cases of the original SARS-CoV-2 strain were observed."
"Combined with a favorable safety and reactogenicity profile, Clover's vaccine candidate utilizing well-established protein-based technology may help to overcome vaccine hesitancy and also warrants its further evaluation as a potential universal COVID-19 booster vaccine."
"Clover remains committed to making SCB-2019 (CpG 1018/Alum) available as quickly as possible to populations in need around the world."
Clover is in the process of submitting conditional regulatory approval applications to the NMPA, EMA, and the WHO and plans to commence product launch post conditional approval.
Clover Biopharmaceuticals is a global clinical-stage biotechnology company located in Chengdu, China, committed to developing novel vaccines and biologic therapeutic candidates. The Trimer-Tag™ technology platform is a product development platform for creating novel vaccines and biologic therapies.